Literature DB >> 31975963

Treatment for Substance Use Disorder With Co-Occurring Mental Illness.

Muhammad N Iqbal1, Charles J Levin1, Frances R Levin1.   

Abstract

Substance use disorder is a highly prevalent condition, leading to significant morbidity, mortality, and burden on the health care system. Substance use disorders are overrepresented among individuals with a mental illness. The term "dual diagnosis" was introduced by the World Health Organization in the mid-1990s and refers to the co-occurrence of a substance use disorder with mental illness-a more recently used term is "co-occurring disorders." In the past decade, substantial progress has been made toward expanding psychotherapeutic and pharmacotherapeutic treatments for treating co-occurring disorders. Yet management remains a challenge among clinicians and has been a source of confusion and considerable controversy. This review describes the epidemiology and treatment of co-occurring disorders, with a focus on major depressive disorder, anxiety disorders, and attention-deficit hyperactivity disorder. Substance use may make diagnosis of the underlying psychiatric condition difficult, and a period of abstinence may be necessary. Findings from efficacy studies of medications used to treat co-occurring disorders are reviewed, as are results of preliminary studies of newer treatments, such as topiramate, ketamine, noninvasive brain stimulation, and deep brain stimulation. Treatment recommendations that combine medications and psychosocial interventions are summarized.
Copyright © by the American Psychiatric Association.

Entities:  

Keywords:  ADHD; Alcohol use disorder; Anxiety disorders; Depression; Dual diagnosis

Year:  2019        PMID: 31975963      PMCID: PMC6526999          DOI: 10.1176/appi.focus.20180042

Source DB:  PubMed          Journal:  Focus (Am Psychiatr Publ)        ISSN: 1541-4094


  155 in total

1.  Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder.

Authors:  F B Taylor; J Russo
Journal:  J Clin Psychopharmacol       Date:  2001-04       Impact factor: 3.153

Review 2.  Integrated psychological treatment for substance use and co-morbid anxiety or depression vs. treatment for substance use alone. A systematic review of the published literature.

Authors:  Morten Hesse
Journal:  BMC Psychiatry       Date:  2009-02-20       Impact factor: 3.630

Review 3.  Ketamine as a rapid-acting agent for suicidal ideation: A meta-analysis.

Authors:  Francesco Bartoli; Ilaria Riboldi; Cristina Crocamo; Carmen Di Brita; Massimo Clerici; Giuseppe Carrà
Journal:  Neurosci Biobehav Rev       Date:  2017-03-23       Impact factor: 8.989

Review 4.  Review of treatment recommendations for persons with a co-occurring affective or anxiety and substance use disorder.

Authors:  Katherine E Watkins; Sarah B Hunter; M Audrey Burnam; Harold Alan Pincus; Gina Nicholson
Journal:  Psychiatr Serv       Date:  2005-08       Impact factor: 3.084

5.  Repetitive transcranial magnetic stimulation (rTMS) for treatment of alcohol dependence.

Authors:  Jacqueline Höppner; Thomas Broese; Lutz Wendler; Christoph Berger; Johannes Thome
Journal:  World J Biol Psychiatry       Date:  2011-09       Impact factor: 4.132

6.  Prevalence and characteristics of adolescents patients with co-occurring ADHD and substance dependence.

Authors:  Susan Merle Gordon; Frank Tulak; Joseph Troncale
Journal:  J Addict Dis       Date:  2004

7.  Repeated high-frequency transcranial magnetic stimulation over the dorsolateral prefrontal cortex reduces cigarette craving and consumption.

Authors:  Revital Amiaz; Dino Levy; Dana Vainiger; Leon Grunhaus; Abraham Zangen
Journal:  Addiction       Date:  2009-01-12       Impact factor: 6.526

Review 8.  Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis.

Authors:  Edward V Nunes; Frances R Levin
Journal:  JAMA       Date:  2004-04-21       Impact factor: 56.272

9.  Reduced intra-individual reaction time variability during a Go-NoGo task in detoxified alcohol-dependent patients after one right-sided dorsolateral prefrontal HF-rTMS session.

Authors:  S C Herremans; M-A Vanderhasselt; R De Raedt; C Baeken
Journal:  Alcohol Alcohol       Date:  2013-05-24       Impact factor: 2.826

10.  Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.

Authors:  Mark J Niciu; David A Luckenbaugh; Dawn F Ionescu; Erica M Richards; Jennifer L Vande Voort; Elizabeth D Ballard; Nancy E Brutsche; Maura L Furey; Carlos A Zarate
Journal:  Int J Neuropsychopharmacol       Date:  2014-10-31       Impact factor: 5.176

View more
  6 in total

1.  Progress and Future: Meeting the Needs of the Nation's Substance Use Crisis.

Authors:  Justine W Welsh; Joji Suzuki
Journal:  Focus (Am Psychiatr Publ)       Date:  2019-04-10

2.  Psychiatric and substance use disorders in a predominately low-income, black sample in early midlife.

Authors:  Christina F Mondi; Alison Giovanelli; Suh-Ruu Ou; Arthur J Reynolds
Journal:  J Psychiatr Res       Date:  2022-02-16       Impact factor: 4.791

3.  Organizational Capacity and Readiness to Provide Medication for Individuals with Co-Occurring Alcohol Use Disorders in Public Mental Health Settings.

Authors:  Katherine E Watkins; Sarah B Hunter; Catherine C Cohen; Isabel Leamon; Brian Hurley; Michael McCreary; Allison J Ober
Journal:  Adm Policy Ment Health       Date:  2021-01-02

4.  'The Drugs Did For Me What I Couldn't Do For Myself': A Qualitative Exploration of the Relationship Between Mental Health and Amphetamine-Type Stimulant (ATS) Use.

Authors:  Liam Patrick Spencer; Michelle Addison; Hayley Alderson; William McGovern; Ruth McGovern; Eileen Kaner; Amy O'Donnell
Journal:  Subst Abuse       Date:  2021-12-06

5.  Barriers to retention in substance use treatment: Validation of a new, theory-based scale.

Authors:  Sarah E Zemore; Orrin D Ware; Paul A Gilbert; Miguel Pinedo
Journal:  J Subst Abuse Treat       Date:  2021-04-21

Review 6.  Repetitive transcranial magnetic stimulation as a potential treatment approach for cannabis use disorder.

Authors:  Tonisha Kearney-Ramos; Margaret Haney
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2021-03-04       Impact factor: 5.201

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.